Liam Ratcliffe

“Liam has been an outstanding sounding board and source of experienced insight on issues, big and small, given his broad drug development background. New Leaf is the perfect partner for a clinical development stage start-up.”

Bruce McCarthy, Former Chief Executive Officer, Afferent Pharmaceuticals, Inc.

Liam Ratcliffe

Managing Director, New York, NY

liam@nlvpartners.com
646-871-6400
Liam Ratcliffe is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including Lyrica, Chantix and Geodon. In previous roles, he gained extensive experience in early drug development and translational research across multiple therapeutic areas, including inflammation, pain, cardiovascular disease, infectious diseases and genito-urinary medicine.
Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Liam also serves on various industry panels, including the Leadership Counsel of the University of Michigan Life Sciences Institute, the Advisory Council of the Keck Graduate Institute, the Life Sciences Advisory Panel of Frankel Consulting and the Pfizer External Advisory Panel for Ophthalmology, the AstraZeneca External Advisory Panel for Research & Development Strategy and Anti-Infectives.

Board Seats and Investments

Notable Alumni Investments

Acadia Pharmaceuticals (NASDAQ: ACAD)
Afferent Pharmaceuticals (Acquired by Merck)
Array BioPharma (NASDAQ: ARRY)
Convergence Pharmaceuticals (Acquired by Biogen Idec)
Epizyme